Davunetide is an eight-amino-acid peptide cut from a brain protein called activity-dependent neuroprotective protein (ADNP). It reached a phase 2/3 trial in progressive supranuclear palsy, where it showed no benefit. This guide covers its structure, proposed mechanism, trials, reported side effects and regulatory status. Sources were checked on November 17, 2026.
Quick answer: Davunetide, also called NAP or AL-108, is an investigational peptide, not an approved drug. Its original developer, Allon Therapeutics, said in 2012 it would put no more capital into the program after a failed trial. It now holds a US orphan designation for ADNP syndrome, a rare neurodevelopmental disorder. No davunetide trial is listed as active on ClinicalTrials.gov.
Vitrapep does not sell davunetide; this page is a reference summary of published research and regulatory information.
What is davunetide?
Davunetide is a short, linear peptide. Its sequence is NAPVSIPQ: asparagine, alanine, proline, valine, serine, isoleucine, proline and glutamine. PubChem lists it as residues 354 to 361 of human ADNP, with the code names AL-108 and AL-208 (PubChem CID 9832404). PubChem gives the formula C36H60N10O12 and a molecular weight of 824.9 g/mol.
It counts as a peptide because it is a chain of eight amino acids joined by peptide bonds. Our peptide primer explains the basics. The parent protein was described in 1999. Bassan and colleagues reported an 828-amino-acid mouse protein that contains the NAPVSIPQ sequence (Bassan et al., 1999).
Davunetide: key facts
| Fact | Detail |
|---|---|
| Structure type | Linear peptide of 8 amino acids (NAPVSIPQ) |
| Class | ADNP-derived neuroprotective peptide (investigational) |
| Molecular formula | C36H60N10O12 |
| Molecular weight | 824.9 g/mol |
| Development stage | Phase 2/3 trial in progressive supranuclear palsy completed in 2012 without benefit; no active registered trial |
| Sponsor or developer | Allon Therapeutics (trials 2006 to 2012); Exonavis Therapeutics (FDA orphan designation sponsor) |
How does davunetide work?
Its proposed mechanism comes from cell and animal work. In the 1999 discovery paper, NAP protected cultured nerve cells at subfemtomolar concentrations. The toxins tested included beta-amyloid, NMDA and an HIV envelope protein (Bassan et al., 1999). In newborn mice lacking apolipoprotein E, treatment sped up developmental reflexes and prevented short-term memory deficits.
Later work focused on microtubules, the protein tracks that give nerve cells their shape. The phase 2/3 trial report summarizes preclinical data suggesting davunetide stabilizes microtubules and reduces tau phosphorylation (Boxer et al., 2014). Those findings led to a trial in progressive supranuclear palsy, a tau-linked brain disease. For background on how short peptides act on cells, see how peptides work.
What is davunetide being studied for?
Davunetide is not approved by the FDA for any use. ClinicalTrials.gov lists five davunetide studies, all completed by the end of 2012:
- mild cognitive impairment, phase 2, 144 people, Allon Therapeutics (NCT00422981);
- mild cognitive impairment after coronary artery bypass surgery, phase 2, 234 people, Allon Therapeutics (NCT00404014);
- schizophrenia, phase 2, 63 people, University of California, Los Angeles (NCT00505765);
- predicted tauopathies, phase 1 pilot, 12 people, University of California, San Francisco (NCT01056965); and
- progressive supranuclear palsy, phase 2/3, 313 people, Allon Therapeutics (NCT01110720).
On December 18, 2012, Allon said the PSP trial “failed to demonstrate efficacy in this population.” It added that it would not allocate additional capital to davunetide research “at this time” (Allon Therapeutics, 2012).
Interest has since moved to ADNP syndrome. FDA designated davunetide an orphan drug for this condition on February 22, 2018. The listed sponsor is Exonavis Therapeutics (FDA orphan database). On its website, Exonavis describes a planned phase 3 study in 97 children with ADNP syndrome across five countries (Exonavis). We found no matching ClinicalTrials.gov record.
What did the key trials show?
Progressive supranuclear palsy. This randomized, double-blind, placebo-controlled phase 2/3 trial ran at 48 centres in six countries. It randomized 313 people: 157 to davunetide and 156 to placebo. The two primary outcomes were the PSP Rating Scale and the Schwab and England daily-living scale. Neither differed between groups. The median change on the PSP Rating Scale was 11.8 points in both arms (p = 0.41). The daily-living result was also flat (p = 0.92) (Boxer et al., 2014). The authors concluded davunetide is not an effective PSP treatment. Allon Therapeutics funded the trial.
Schizophrenia. A randomized, double-blind trial in 63 patients added davunetide or placebo to antipsychotic treatment. Change on the MATRICS cognitive battery did not differ from placebo (p = 0.45). A test of everyday functional skills, the UPSA, showed a significant treatment effect (p = 0.048) (Javitt et al., 2012).
Mild cognitive impairment. A randomized, placebo-controlled study enrolled 144 people with amnestic mild cognitive impairment. It found no significant difference in its composite memory score (Morimoto et al., 2013). Some single memory and attention tasks showed what the authors called signals of potential efficacy.
A 2024 re-analysis of that trial split results by sex and reported different patterns in men and women (Gozes et al., 2024). The authors disclosed a patent application licensed to Exonavis. All of the studies above were in humans.
What side effects have studies reported?
In the PSP trial, serious adverse events were equal, with 54 in each group. There were 11 deaths with davunetide and 10 with placebo. Three nose-related events were more common with davunetide:
- nosebleeds: 12% vs 8%;
- runny nose: 10% vs 5%; and
- nasal discomfort: 10% vs under 1% (Boxer et al., 2014).
The schizophrenia trial reported no significant side effects or adverse events (Javitt et al., 2012). The mild cognitive impairment study described davunetide as generally safe and well tolerated. We found no published safety results from studies in ADNP syndrome.
What is davunetide’s regulatory status, and how is it used in research?
Davunetide is an investigational compound in the United States. Its FDA orphan record lists it as “Not FDA Approved for Orphan Indication.” An orphan designation is not a marketing approval. A search of fda.gov found no warning letter or import alert that names davunetide.
In the laboratory, NAP remains a research tool for nerve-cell and microtubule studies. A PubMed search today returned 82 records that mention davunetide in the title or abstract (PubMed). Our guide to research-use-only labels explains why such labels do not make a compound approved.
Frequently asked questions about davunetide
Is davunetide a peptide?
Yes. It is a linear chain of eight amino acids, NAPVSIPQ, taken from the ADNP protein.
Is davunetide FDA approved?
No. It holds a 2018 FDA orphan designation for ADNP syndrome, which is not an approval.
Are davunetide, NAP and AL-108 the same thing?
Yes. PubChem lists NAP, AL-108 and AL-208 as names for davunetide. AL-108 and AL-208 were codes for two different formulations.
Did davunetide work in progressive supranuclear palsy?
No. In a 313-person trial, neither primary outcome differed from placebo.
Is davunetide being tested in ADNP syndrome?
Exonavis describes a planned phase 3 study on its website. We found no ClinicalTrials.gov registration for it.
What to know now
- Structure: linear peptide of 8 amino acids (NAPVSIPQ); 824.9 g/mol.
- Origin: a fragment of activity-dependent neuroprotective protein (ADNP).
- Status: not FDA-approved; orphan designation for ADNP syndrome since 2018.
- Evidence: no benefit on either primary outcome in a 313-person PSP trial.
- Safety: serious adverse events 54 vs 54 in the PSP trial; nose-related events more common.
- Registry: five completed trials; none listed as active.
What we’re watching
A ClinicalTrials.gov registration or published results for the phase 3 study in ADNP syndrome that Exonavis describes. Further sex-stratified analyses of the earlier trials. Related guides: NNZ-2591, cerebrolysin and trofinetide.